Genmab | GEN - Net Income

Stock Price
1,851.50
Daily Change
19.00 1.04%
Monthly
-12.25%
Yearly
13.10%
Q1 Forecast
1,757.86

Genmab reported DKK336M in Net Income for its fiscal quarter ending in June of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Almirall EUR 19.58M 7M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
argenx SE USD 344.26M 98.9M Sep/2025
AstraZeneca USD 2.33B 207M Dec/2025
Bayer EUR -963M 764M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Demant DKK 427M 690M Dec/2025
Exelixis USD 193.58M 8.73M Sep/2025
Fresenius Medical Care EUR 327M 52.2M Dec/2025
Galapagos EUR -202.11M 96.36M Sep/2025
Genmab DKK 336M 141M Jun/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
GN Store Nord DKK 344M 271M Dec/2025
GRIFOLS EUR 126.96M 9.9M Sep/2025
Hikma Pharmaceutical USD 119M 14M Jun/2025
Insmed USD -328.48M 41.54M Dec/2025
Lonza CHF 307M 22M Dec/2024
Merck EUR 902M 250M Sep/2025
Novartis USD 3.93B 96M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
UCB EUR 857M 649M Dec/2024